Xu Deng

Xu Deng

Auto-generated profile, based on publicly available information

Xu Deng

Xiangya School of Pharmaceutical Science, Central South University, Changsha, 410013, Hunan, China; Hunan Key laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South University, Changsha, 410013, Hunan, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2018 in Natural Product Research
Verified
Journal Article
Closed access
GZGuangyao Zeng
Guangyao Zeng
ZWZhaoquan Wu
Zhaoquan Wu
WCWei Cao
Wei Cao
YWYajing Wang
Yajing Wang
XDXu Deng
Xu Deng
YZYingjun Zhou
Yingjun Zhou
The pollen of T. angustifolia, also known as Pu huang in Chinese, has been used for treatment of stranguria, hematuria, dysmenorrhea, metrorrhagia and injuries in China for a long time. Extensive efforts have been directed toward its phytochemical and biological aspects. However, little is known about its anti-nociceptive implication and material basis. This work presented the investigation of the anti-nociceptive effect of Typhae Pollen using an effect-directed fractionation strategy, thereby leading to identification of isorhamnetin-3-O-neohesperidin (1) and typhaneoside (2), together with other minor flavonoid glycoside congeners, as the main anti-nociceptive constituents. This work not only unveils the anti-nociceptive potential of Typhae Pollen, but also establishes a method to enrich and identify the anti-nociceptive constitutes of Typhae Pollen. Moreover, this work is a successful example of effect-directed fractionation strategy, which represents a powerful tool in TCM-based drug discovery and development.

1 April 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JMJinjin Ma
Jinjin Ma
LCLan Chen
Lan Chen
JFJinbao Fan
Jinbao Fan
WCWei Cao
Wei Cao
GZGuangyao Zeng
Guangyao Zeng
XDXu Deng
Xu Deng

3 May 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BPBhavin V. Pipaliya
Bhavin V. Pipaliya
DTDaria N. Trofimova
Daria N. Trofimova
RGRebecca L. Grange
Rebecca L. Grange
MAMadhu Aeluri
Madhu Aeluri
XDXu Deng
Xu Deng
PEP. Andrew Evans
P. Andrew Evans

27 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
XDXu Deng
Xu Deng
LSLi-Yang Shi
Li-Yang Shi
JLJialing Lan
Jialing Lan
YGYu-Qing Guan
Yu-Qing Guan
XZXiaoyong Zhang
Xiaoyong Zhang
XZXumu Zhang
Xumu Zhang
Transition-metal-catalyzed cycloisomerization of 1,n-allenynes represents a powerful synthetic tool to rapidly assemble complex polycyclic skeletons from simple linear substrates. Nevertheless, there are no reports of the asymmetric version of these reactions. Moreover, most of these reactions proceed through a 6-endo-dig cyclization pathway, which preferentially delivers the distal product (via 5/5 rhodacyclic intermediate) rather than the proximal one (via 6/5 rhodacyclic intermediate). Herein, we report an enantioselective rhodium(I)-catalyzed cycloisomerization of 1,6-allenynes to provide the proximal product 5/6-fused bicycle[4.3.0]nonadienes in good yields and with excellent enantioselectivities. Remarkably, this chemistry works perfectly for 1,6-allenynes having a cyclic substituent within the allene component, thereby affording synthetically formidable tricyclic products with excellent enantioselectivities. Moreover, extensive DFT calculations suggest an uncommon pathway involving 5-exo-dig cycloisomerization, ring-expansion, rate-determining alkene isomerization involving Csp3-H activation, C-C activation of the cyclobutene moiety and finally reductive elimination. Deuterium labeling experiments support the rate-determining step involving the C–H bond activation in this transformation.

19 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SYShu-Ting Yang
Shu-Ting Yang
JFJin-Bao Fan
Jin-Bao Fan
TLTing-Ting Liu
Ting-Ting Liu
SNShuai Ning
Shuai Ning
JXJia-Hao Xu
Jia-Hao Xu
XDXu Deng
Xu Deng

18 April 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TLTing-Ting Liu
Ting-Ting Liu
QWQing Wang
Qing Wang
YZYuxing Zhou
Yuxing Zhou
BYBaixin Ye
Baixin Ye
TLTingting Liu
Tingting Liu
XDXu Deng
Xu Deng